Return to site
Return to site

MoleculeMind Secures Strategic Investment of Over 100 Million Yuan for AI Protein Design Platform

Pioneering Robotics and AI Solutions Provider to Enhance R&D Capabilities and Foster Global Biopharmaceutical Advancements

· Trends

China's AI protein design platform company, MoleculeMind, has announced receiving a strategic investment of over 100 million yuan. The investment will be used to further develop their AI protein optimization and design platform, MoleculeOS, and explore its applications in biopharmaceuticals and synthetic biology. MoleculeMind, established just one year ago, has already completed two rounds of financing.

 

Founded by Professor Xu Jinbo, a prominent computational biologist in the field of AI protein folding, MoleculeMind's research laid the foundation for the development of AlphaFold and demonstrated the possibility of using deep learning methods to predict protein structures.

 

Drawing on years of team experience, MoleculeMind independently developed the first fully functional AI-driven protein prediction and design platform in China, called "MoleculeOS." This platform utilizes data-driven AI techniques to rapidly identify, modify, and even design the most suitable proteins. It can be applied in the research and design of peptides, antibodies, enzymes, and small proteins, making the development of large-molecule innovative drugs predictable and programmable, thus improving drug development efficiency. Additionally, the platform can also optimize and design proteins in fields such as chemistry, materials, industry, and agriculture, disrupting the research paradigms in the areas of large-molecule drug design, synthetic biology, and environmental protection.

 

 

Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.

 

Subscribe
Previous
The Brilliant Orange-Red Guiding Light - CY3 Phosphoramidite
Next
Eluminex Biosciences Raises Over $40 Million in Series B...
 Return to site
Cookie Use
We use cookies to improve browsing experience, security, and data collection. By accepting, you agree to the use of cookies for advertising and analytics. You can change your cookie settings at any time. Learn More
Accept all
Settings
Decline All
Cookie Settings
Necessary Cookies
These cookies enable core functionality such as security, network management, and accessibility. These cookies can’t be switched off.
Analytics Cookies
These cookies help us better understand how visitors interact with our website and help us discover errors.
Preferences Cookies
These cookies allow the website to remember choices you've made to provide enhanced functionality and personalization.
Save